Are Royal Mail PLC & AstraZeneca plc Perfect Income Stocks?

Roland Head asks if Royal Mail PLC (LON:RMG) and AstraZeneca plc (LON:AZN) are essential buys for long-term income investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The perfect dividend stock needs a special mix of profitability, good cash flow and staying power.

Finding companies like these at the right price isn’t easy. For example, ARM Holdings fits the bill, but the high share price and 1% yield means the tech firm isn’t much use for anyone who needs a usable income.

Two companies I believe could make the grade are Royal Mail (LSE: RMG) and AstraZeneca (LSE: AZN).

Royal Mail

Royal Mail shares popped 5% higher this morning, after the postal operator increased its cost-cutting target for the year and reported first-half profits in-line with expectations.

Adjusted operating profits excluding transformation costs were down by £6m to £342m. However, underlying operating costs are now expected to fall by 1% this year, versus a previous forecast for flat costs.

The interim dividend has risen by 4.5% to 7p. Analysts expect a total payout of 21.8p this year, giving a forecast yield of 4.5% at the current 480p share price. This should be covered comfortably by forecast earnings of 34.5p per share.

There was good news operationally, too. While letter volumes continue to decline, Royal Mail’s saw a 4% increase in parcel volumes in its main postal business, along with a 9% increase in volumes in the GLS (Parcelforce) business. This suggests the group may be winning new market share in the all-important online shopping sector.

My only real concern is that the extensive cost cutting being pushed through by chief executive Moya Greene could end up limiting growth potential. In total, 3,000 staff left the business during the first half. The group plans to spend £180m on transformation costs this year, as part of a total investment in the business of £620m. Royal Mail says this is “similar to last year”.

To justify this kind of expenditure, shareholders will need to see decent growth over the next few years.

Notwithstanding this risk, I believe Royal Mail is an appealing income buy following today’s results.

AstraZeneca

When a company receives a takeover offer which then falls through, the share price often drops back to the level it was at before the offer was received.

Interestingly, that hasn’t happened with AstraZeneca shares. The current £44 share price is around 15% higher than the £38 level at which Astra shares traded before Pfizer tried to buy the Anglo-Swedish business.

This suggests to me that the market is confident that AstraZeneca’s pipeline of new products will deliver strong long-term growth. Although profits have fallen heavily since 2011, I believe this long-term view is correct.

Earnings are expected to rise by 11% to $4.25 per share this year, giving a forecast P/E of 16. The dividend is likely to remain unchanged again, but given the 4.1% yield I can accept that for a few years.

One of the things I like most about AstraZeneca is its strong balance sheet. Net debt remains relatively low, at $6.4bn, giving net gearing of only 36%. Cash generation is good, too. On average, the dividend has been covered by free cash flow every year since at least 2009.

AstraZeneca is one of star fund manager Neil Woodford’s biggest holdings. I can see why. For long-term income and growth, I believe these shares are a strong buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »